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Abstract
Acute exposure to lipopolysaccharide (LPS) can cause hypoglycemia and insulin resistance; the
underlying mechanisms however, are unclear. We set out to determine whether insulin resistance
is linked to hypoglycemia through TLR4, MyD88 and NFκB, a cell signaling pathway that
mediates LPS induction of the proinflammatory cytokine TNFα. LPS induction of hypoglycemia
was blocked in TLR4−/− and MyD88−/− mice but not in TNFα−/− mice. Both glucose production
and glucose utilization were decreased during hypoglycemia. Hypoglycemia was associated with
the activation of NFκB in the liver. LPS inhibition of glucose production was blocked in
hepatocytes isolated from TLR4−/− and MyD88−/− mice and hepatoma cells expressing an IκB
mutant that interferes with NFκB activation. Thus, LPS-induced hypoglycemia was mediated by
the inhibition of glucose production from the liver through the TLR4, MyD88, NFκB pathway,
independent of LPS induced TNFα. LPS inhibition of glucose production was not blocked by
pharmacologic inhibition of the insulin signaling intermediate PI3K in hepatoma cells. Insulin
injection caused a similar reduction of circulating glucose in TLR4−/− and TLR4+/+ mice. These
two results suggest that LPS and insulin inhibit glucose production by separate pathways.
Recovery from LPS induced hypoglycemia was linked to glucose intolerance and
hyperinsulinemia in TLR4+/+ mice, but not in TLR4−/− mice.
Conclusion—Insulin resistance is linked to the inhibition of glucose production by the TLR4,
MyD88 and NFκB pathway.
Lipopolysaccharide (LPS) from Gram-negative bacterial infection can cause hypoglycemia
and insulin resistance in both humans and mice; however, the underlying mechanisms are
unclear (1-5). Low levels of LPS exposure through gastrointestinal tract and air-borne
particles can also lead to insulin resistance (6-8). Thus, insulin resistance is decreased in
mice by antibiotic treatment or housing in germ-free facilities (9,10). Insulin resistance is
also decreased by gene deletion of Toll-like receptor-4 (TLR4) or a cluster of differentiation
14 (CD14), a glycoprotein that binds to the extracellular portion of TLR4 (11-13). TLR4 is a
plasma membrane protein that mediates LPS induction of inflammatory cytokines such as
tumor necrosis factor alpha (TNFα) and interleukin-1 beta (IL-1β) (14). The main goals of
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this study were to (a) determine whether TLR4 and its downstream signaling targets mediate
the induction of hypoglycemia by LPS and, if so, (b) determine whether the induction of
hypoglycemia by TLR4 is linked to the development of insulin resistance.
LPS was postulated to cause hypoglycemia through the induction of the cytokines TNFα and
IL-1β (15). Given that LPS does not induce hypoglycemia in IL-1α−/− and IL-1β−/−
“double-knockout” mice, LPS induction of IL-1β is essential (16). Whether LPS induction
of TNFα plays an essential role is unclear. LPS induction of TNFα causes hypoglycemia on
the basis that (a) hypoglycemia coincides with LPS induction of TNFα, (b) the time course
of hypoglycemia is similar when mice are injected with LPS or recombinant TNFα, and (c)
LPS does not trigger hypoglycemia in C3H/HeJ mice, an inbred strain in which LPS
injection does not induce TNFα based on a loss of function mutation in the TLR4 gene
(15,17). However, neutralizing antibodies against TNFα do not impair LPS induction of
hypoglycemia, suggesting that TNFα does not play a role (18,19).
LPS induction of IL-1 and TNFα is triggered by the interaction of Toll/interleukin-1
receptor (TIR) domains on the intracellular portion of TLR4 and TIR domains on myeloid
differentiation factor 88 (MyD88) (20). However, TLR4 can also mediate its effects by
interacting with TIR domains on other adaptors. LPS induction of interferon beta, for
example, is mediated by the TIR domain-containing adaptor TRIF (21). Whether LPS
induction of hypoglycemia is mediated by TLR4 and MyD88 is currently not known.
LPS may cause hypoglycemia by inhibiting glucose production through nuclear factor kappa
B (NFκB), a downstream target of MyD88. NFκB is a heterodimer of two DNA-binding
subunits, p50 and p65 (22). Under basal conditions, NFκB is retained in the cytoplasm by
the inhibitor of NFκB (IκB). The translocation of NFκB to the nucleus is induced by
phosphorylation of IκB. MyD88 activates NFκB by stimulating IL-1R-associated kinase
(IRAK) which recruits the tumor necrosis factor receptor-associated factor (TRAF6) (21).
TRAF6 phosphorylates IκB kinase beta (IKKβ) which leads to ubiquitination and
degradation of IκB by SCF-b-TrCP and the 26S proteasome, respectively (23).
The role of NFκB in LPS induction of hypoglycemia is unclear. NFκB inhibits glucose
production induced by glucocorticoid and glucagon (24). Acute LPS exposure lowers the
expression and activity of rate limiting enzymes in glucose production, glucose-6-
phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) (25,26). IL-1 and
TNFα suppress the gene expression of G6Pase and PEPCK by activating NFκB (27,28).
Activation of NFκB can also inhibit glucose production by stimulating the production of
nitric oxide (NO) (26). NFκB increases NO production in hepatocytes by stimulating
inducible nitric oxide synthase (iNOS) expression (29). However, it is not known whether
LPS induction of hypoglycemia is mediated by NFκB.
Insulin is the most potent physiologic inhibitor of glucose production. LPS does not
stimulate insulin secretion, but it is unknown whether LPS causes hypoglycemia by
engaging the insulin signaling pathway (30). Insulin inhibits glucose production by
suppressing G6Pase expression through phosphatidylinositol 3-kinase (PI3K) (31). Insulin
activation of PI3K causes a transient increase of phosphatidylinositol-3,4,5-phosphate
(PI3P) in cell membranes, which activates protein kinase B (PKB), also known as Akt,
causing the phosphorylation and nuclear exclusion of Foxo1, a member of the Forkhead/
winged helix family of transcription factors (32). LPS exposure leads to PI3K activation in
neutrophils (33). It is unknown whether LPS causes hypoglycemia by inhibiting glucose
production through PI3K.
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Three to six month old male C57Bl/6 mice were used. TLR4−/− and MyD88−/− mice were
obtained from Osaka University (14,34). TNFα−/− mice were obtained from the Jackson
Laboratory (35). All mice were fed a standard chow diet (73% carbohydrate, 18% protein,
4% fat, 5% ash) and housed in ventilated isolator cage systems in pathogen-free barrier
facilities at the University of North Carolina. The colony was maintained on a 12-hour light/
dark cycle at 23°C and 55% humidity. Experimental procedures were approved by the
Institutional Animal Care and Use Committees (UNC) in accordance with criteria outlined
in the Guide for the Care and Use of Laboratory Animals (NIH).
Steady State Measurements of Plasma Glucose after LPS Injection
Food was removed from cages at 7 AM. Basal plasma glucose levels were measured at 10
AM; blood was sampled from the tail tip using a cut below the vertebrae. Glucose was
measured by a hand-held glucose meter (One-Touch Ultra; Johnson and Johnson). Mice
were weighed to determine the dose of LPS. LPS (E. coli serotype 0111:B4; Sigma) was
given by a single intra-peritoneal injection. Blood was sampled at indicated times.
Anesthesia and mouse restraining devices were not used for these procedures. TNFα levels
were determined by enzyme-linked immune assay (B&D Biosciences).
Insulin Tolerance Tests
Food was removed at 7 AM. Blood was sampled from the tail tip to determine basal glucose
levels at 10 AM. Mice were weighed to determine the dose of insulin (Humalin R; Eli Lilly).
Insulin was given by intra-peritoneal injection, and plasma glucose was measured at
indicated time points after the injection.
Glucose Tolerance Tests after Recovery from LPS-Induced Hypoglycemia
Mice received LPS or saline by intraperitoneal injection. After complete recovery from LPS-
induced hypoglycemia (48 hours), mice received an intraperitoneal injection of glucose (2.5
mg/kg), and plasma glucose was measured at indicated time points. To determine whether
LPS exposure caused insulin resistance, mice were injected with 0.5, 1, 2 or 4 mg of glucose
per gram body weight, and plasma insulin was measured 15 minutes after injection by radio-
immune assay (LINCO).
Production and Utililization of Circulating Glucose after LPS Injection
At 8 hours after LPS or saline injection, while circulating levels of glucose were stable, trace
amounts of 3H-glucose (D-3-3H-glucose; Amersham Biosciences) in 50-100μl saline were
injected directly into the circulation of conscious, free moving mice through the ophthalmic
plexus, as previously described (36). Blood samples (10-20 μl) were collected from the tail
tip at 0, 3, 6, 9, 12, 15, 18 and 21 minutes after injection of 3H-glucose for glucose and
radioactivity measurements. The disappearance of radioactivity in dried plasma measured by
scintillation counting was similar to the disappearance of 3H-glucose measured by HPLC
analysis on an Agilent 1100 HPLC System (Fig. 2D-E). The rate of glucose utilization was
calculated by multiplying the fractional elimination constant, by the total pool of circulating
glucose and dividing by body weight (37).
Electro Mobility Shift Assays
Nuclear extracts and electro mobility shift assays (EMSAs) were carried out as previously
described (38). Snap frozen livers, isolated 0, 4 and 8 hours after LPS injection, were
crushed in liquid nitrogen and Dounce homogenized in a 0.3 M sucrose buffer. Nuclei were
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isolated by layering and pelleting through 0.88 M and 1 M sucrose solutions. Nuclear
extracts were incubated with a 32P-labeled oligonucleotide (5′-
CAGGGCTGGGGATTCCCATCTCCCACAGTTTCACTTC-3′) corresponding to the
NFκB binding site on the H2-κB gene promoter (38). Reaction mixes were loaded on
nondenaturing 5% polyacrylamide gels in tris-glycine buffer (25 mM Tris, 190 mM
glycine). Gels were dried under vacuum onto filter paper before being exposed against
Kodak X-Omat film at −70 C with an intensifying screen. In competition assays, a 100-fold
molar excess of unlabeled, double-stranded probe was added to the reaction mix before the
addition of the probe. A competitor control was performed. Unlabeled oligonucleotide in
100-fold molar excess was added to the reaction mix before addition of the antiserum.
Isolated Hepatocyte and Hepatoma Cell RT-PCR Assays
Liver was collected from 4-5 mice injected with LPS or saline 4 hours earlier. Reverse
transcriptase II and Plat Quantitative PCR SuperMix-UDG (Invitrogen) and MyiQ Software
were used on a Biorad Thermocycler. G6Pase forward and reverse primers were
ATCTTCTGTTCCACGGAGAGG and CAGAGTGCTCAGGATGTTAAGG, respectively.
Standards, in relative units of RNA, were 10−10, 10−11, 10−12, 10−13 g of liver RNA. R2=
0.818 where y = −2.112x+39.338; Tm was 82-83 C.
Isolated Hepatocyte and Hepatoma Cell Glucose Production Assays
Glucose production was measured in isolated hepatocytes and hepatoma cells as previously
described (36). Freshly isolated rat hepatocytes were plated at 105 cells per well in 12-well
culture plates coated with rat tail collagen I (BD Biosciences). Cells were cultured in 25 mM
glucose Dulbecco’s Modified Eagle Medium (DMEM; Caisson Laboratories) supplemented
with 10% horse serum (HS). After 4 hours, the medium was changed to 25 mM glucose
DMEM supplemented with 2.5% Fetal Bovine Serum (FBS) and 2.5% HS. After 8 hours,
the medium was changed to 5 mM glucose/DMEM/5% HS with or without LPS (2.5 μg/mL)
dissolved in dimethylsulphoxide (DMSO). After 8 hours, the media was changed to glucose-
free and serum-free DMEM containing 5 mM of alanine, glycine, valine, sodium pyruvate
and lactate (Sigma). Cells were incubated in the glucose-free medium for 8 hours. Glucose
secreted into the medium was measured by colorimetric assay (Autokit Glucose CII). Cells
were collected in RIPA lysis buffer and analyzed for total protein (BCA Assay Kit; Pierce).
RIPA lysis buffer consisted of 50 mM Tris-HCl pH 7.5; 150 mM NaCl; 1% Triton-X 100/
NP40; 0.5% sodium deoxycholic acid; 0.1% SDS; 1% PMSF; 1 mM Na3VO4; 0.1%
Aproinin; and 0.1% phosphatase inhibitor (Sigma). Rat hepatoma cells (McArdle RH7777)
were stored in liquid nitrogen at 106 cells/ml. Hepatoma cells were plated at 2.5 to 5.0 × 104
per well. Liver cells were exposed to LPS (2.5 μg/mL), human recombinant (100 nM from
100 U/ml stock where 28.85 U/mg, Elli Lily), LY294002 (33 μM; Calbiochem) or Lipid A
(39).
Isolated Hepatocyte and Hepatoma Cell RT-PCR Assays
Reverse transcriptase II and Plat Quantitative PCR SuperMix-UDG (Invitrogen) and MyiQ
Software were used on a Biorad Thermocycler. G6Pase forward and reverse primers were
ATCTTCTGTTCCACGGAGAGG and CAGAGTGCTCAGGATGTTAAGG, respectively
The standards, in relative units of RNA, were 10−10, 10−11, 10−12, 10−13 g of liver RNA.
Liver was collected from 4-5 mice injected with LPS or saline 8 hours earlier. R2= 0.818;
Y=−2.112X+39.338; Tm was 82-83 C.
Retroviral Transduction
The dominant-negative IκB-SR mutant construct was used to generate an IκB-SR fragment
flanked by EcoRI and ApaI sites (40). This was subcloned into pML2(EGFP-N1) to produce
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the IκB-SR-pML2(EGFP-N1) retroviral construct. HEK293 cells were transfected using a 3
to 1 ratio of IκB-SR-pML2(EGFP-N1) to pCL-ECO and the Fugene transfection reagent.
HEK293 cells were incubated in DMEM/10% FBS at 37 C for 48 hours. The medium was
then changed to DMEM/2.5% FBS and 2.5% HS, and cells were incubated at 32 C for 48
hours to allow retroviral production. The viral-containing medium (6 ml) was removed from
the cells and mixed with 2.67 μg polybrene. The solution was then centrifuged at 3500 rpm
for 5 min at room temperature. The viral supernatant (2 ml/well) was introduced to rat
hepatoma cells (6-well plate) for 12-18 hours. The pML2(EGFP-N1) construct was used as a
control for the effects of transfection. DNA and RNA were isolated (DNeasy and RNeasy
Kits; Qiagen), and RNA was used to prepare cDNA using random hexamers (Superscript;
Invitrogen). Integration of the retroviral IκB-SR construct into DNA and expression of IκB-
SR mRNA were tested by PCR analysis.
Statistics
Significant differences between the groups were examined using a two-tailed, two-sample
unequal-variance Student’s t-test or Tukey-Kramer test. Significance was set at p < 0.05.
RESULTS
The role of TLR4 in LPS induced hypoglycemia was evaluated in TLR4−/− mice (Fig. 1A).
TLR4+/+ and TLR4−/− mice were injected with various doses of LPS and plasma glucose
was measured 4 hours after injection. Plasma glucose was reduced in TLR4+/+ mice but
unchanged in TLR4−/− mice at 0.005, 0.05 and 0.5 mg LPS per kg body weight. The highest
dose of LPS we tried, 5 mg/kg, was lethal. Thus, mice in subsequent studies were injected
with 0.5 mg/kg LPS. The role of MyD88 in the LPS induced hypoglycemia was examined in
MyD88−/− mice (Fig. 1B). MyD88+/+ and MyD88−/− mice were injected with LPS (0.5 mg/
kg). Glucose was lower than preinjection values at 2, 3 and 4 hours after LPS injection in
MyD88+/+ mice, but not in MyD88−/− mice. These results indicate that LPS induced
hypoglycemia is mediated by TLR4 and MyD88.
The role of TNFα in LPS induced hypoglycemia was evaluated in TNFα−/− mice (Fig. 1C).
TNFα+/+ and TNFα−/− mice were injected with LPS (0.5 mg/kg). TNFα was elevated by
LPS in TNFα+/+ mice, but not in TNFα−/− mice. TNFα+/+ and TNFα−/− mice showed
similar reductions in plasma glucose after LPS injection. Therefore, LPS induced
hypoglycemia is not mediated by LPS induction of TNFα.
The acute effects of LPS on glucose production and utilization were examined in wild-type
mice using the intravenous injection of 3H-glucose (Fig. 2A). LPS lowered the rate of
glucose utilization to 9.2 + 1.5 mg/kg/min, compared to 19.1 + 0.9 mg/kg/min in controls
(Fig. 2B). Intravenous injection of 3H-glucose and the sampling of tail blood to determine
the rate of glucose utilization did not alter the concentration of circulating glucose over the
21-minutes used to measure glucose production and utilization (Fig. 2C). The disappearance
of radioactivity in plasma, measured by scintillation counting, showed single phase (Fig.
2D) and was similar to the disappearance of 3H-glucose measured by HPLC analysis (Fig.
2E). Since circulating levels of glucose were stable during the measurement of glucose
utilization, the rate of glucose utilization also reflected the rate of glucose production. Thus,
LPS induced hypoglycemia reduced the rates of glucose utilization and glucose production.
In order to determine whether LPS inhibited glucose production in the liver directly, we
measured glucose production in isolated rat hepatocytes exposed to 2.5 mg/ml LPS (Fig.
2F). Glucose production was measured over 8 hours of LPS exposure. LPS suppressed
glucose production in isolated hepatocytes by 50%. LPS did not affect glucose production in
hepatocytes isolated from TLR4−/− and MyD88−/− mice (data not shown). These results
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suggest that LPS-induced hypoglycemia is mediated by direct inhibition of glucose
production by TLR4 and MyD88.
We postulated the involvement of NFκB in the signaling pathway that inhibits glucose
production. To test this hypothesis, mice livers were isolated 4 hours after injection of LPS
(0.5 mg/kg) or saline and nuclear translocation of NFκB was measured by electromobility
shift assay (EMSA). A double stranded 32P-labeled oligonucleotide probe corresponding to
the binding element of NFκB in the promoter region of the H2-κB gene was used (38).
EMSA revealed an increase in nuclear binding of NFκB after LPS injection injection (Fig.
3A). The elevation of NFkB activation 4 hours after LPS injection was also associated with
a 5- to 10-fold reduction in G6Pase mRNA by RT-PCR (p<0.05).
The rat hepatoma cell line, McArdle RH7777, was used to determine whether LPS inhibition
of glucose production depended on NFκB. Hepatoma cells were transduced by a retroviral
vector encoding green florescent protein (GFP) or GFP and a degradation-resistant IκB
mutant (IκB-SR) that blocks nuclear translocation of NFκB (40). DNA integration and gene
expression of the IκB-SR construct were confirmed by PCR (Fig. 3B). Glucose production
was measured over 8 hours of LPS (2.5 μg/ml) exposure. LPS inhibition of glucose
production was blocked by IκB-SR (Fig. 3C). These results support that LPS inhibition of
glucose production depends on the activation of NFκB. LPS did not inhibit glucose
production by damaging or shutting down hepatocytes and hepatoma cells. In our
experience, adherent hepatocytes and hepatoma cells undergoing necrosis or apoptosis by
inhibition of mTOR, for example, show reduced protein content. We did not observe a
significant change in protein content after 8-16 hours of LPS exposure (2.5 μg/ml).
Furthermore, Hoescht and trypan blue staining did not reveal any aberrant decrease the
health status of the cells under the conditions described.
Two experiments were performed to determine whether LPS and insulin inhibit glucose
production by different pathways. Rat hepatoma cells were either untreated or treated with
insulin or insulin and LY294002 and exposed to LPS (Fig. 4A). LY294002 is an inhibitor of
the insulin signaling intermediate PI3K. LY294002 did not interfere with LPS inhibition of
glucose. Furthermore, the combination of insulin and LPS showed additive effects. TLR4+/+
and TLR4−/− mice were injected with insulin (0.75 U/kg), and plasma glucose production
was measured after 15, 30, 45, 60, 90 and 120 minutes (Fig. 4B). The absence of TLR4 did
not alter the acute effect of insulin injection on glucose. Therefore, LPS and insulin may
inhibit glucose production by different pathways.
TLR4+/+ and TLR4−/− mice received an intraperitoneal injection of glucose 48 hours after
injection of LPS. This period (48 hours) allowed complete recovery from LPS-induced
hypoglycemia in TLR4+/+ mice. Plasma glucose was measured at 0 and 15, 30, 60, 90 and
120 minutes after the injection of glucose (Fig. 5A). TLR4+/+ and LPS-induced
hypoglycemia was associated with glucose intolerance at 15 and 30 minutes after glucose
injection (2.5 g/kg). Glucose intolerance is often associated with insulin resistance.
Therefore, to determine whether insulin resistance is linked to LPS-induced hypoglycemia,
insulin was measured 15 minutes after the injection of glucose (0.5, 1.0, 2.0 or 4.0 g/kg).
Hyperinsulinemia, a hallmark of insulin resistance, was evident in TLR4+/+ mice previously
exposed to LPS at each glucose dose (Fig. 5B). The absence of glucose intolerance and
hyperinsulinemia in LPS-injected TLR4−/− mice suggests that insulin resistance is a
secondary effect of LPS-induced hypoglycemia through the TLR4, MyD88, NFκB pathway.
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This study provides the first evidence that LPS-induced hypoglycemia is mediated by the
inhibition of glucose production through the TLR4, MyD88, NFκB pathway. The inability
of LPS to induce hypoglycemia in TLR4−/− and MyD88−/− mice clearly shows that LPS
induction of hypoglycemia is mediated by TLR4 and MyD88. LPS induction of
hypoglycemia was not impaired in TNFα−/− mice, suggesting that IL-1 may be the only
essential cytokine for LPS induction of hypoglycemia (16). MyD88 may be essential for the
induction of hypoglycemia for both TLR4 and the IL-1 receptor as the cytosolic regions of
TLR4 and the IL-1 receptor contain TIR domains that can interact with TIR domains on
MyD88 (14,20,34,41).
LPS injection transiently decreased both glucose production and glucose utilization.
Although numerous tracer studies have shown that acute exposure to LPS inhibits glucose
production, there are conflicting reports about the effect of LPS on glucose uptake (42,43).
In the present study, the effect of LPS on glucose production and utilization was measured
during LPS induced hypoglycemia. The importance of circulating glucose levels for glucose
uptake was previously demonstrated; glucose uptake was reduced under LPS-induced
hypoglycemia but increased when euglycemia was restored by glucose infusion (44).
Therefore, under physiologic conditions in vivo, LPS induced hypoglycemia is associated
with the reduction of glucose production and utilization.
TLR4 and MyD88 inhibition of glucose production in vivo may depend on NFκB since we
showed that (a) nuclear translocation of NFκB in the liver was increased by LPS injection,
and (b) suppression of NFκB activity in hepatoma cells, through an IκB mutant, blocked
LPS inhibition of glucose production. Two other targets of TLR4 and MyD88, p38 mitogen-
activated protein kinase (p38 MAPK) and c-Jun NH2-terminal kinase (JNK), are linked to
high glucose production and hyperglycemia (45,46). Therefore, NFκB is a downstream
target of TLR4 capable inducing hypoglycemia by inhibiting liver glucose production.
LPS inhibition of glucose production was not influenced by PI3K activity. PI3K inhibition
in hepatoma cells has also failed to interfere with the suppression of G6Pase expression by
TNFα (27). These observations suggest that LPS, IL-1 and TNFα regulate glucose
metabolism in the liver by a different signaling mechanism than insulin. Crosstalk between
the LPS and insulin signaling pathways may occur at the level of gene expression by NFκB
and Foxo-1 (32). Crosstalk between the TLR4 and insulin signaling pathways has been
reported in myeloid cells (47). LPS induced decreases in blood flow can also contribute to
low glucose utilization after LPS injection (48).
Insulin resistance was evident after LPS exposure in vivo. Insulin resistance may be part of a
systemic counter-regulatory response to LPS-induced hypoglycemia aimed at restoring
circulating glucose. The mechanism may be linked to the elevation of proinflammatory
cytokines as well as counter-regulatory hormones such as catecholamines, glucagon and
glucocorticoids (8,49-51). This is consistent with the observation that insulin infusion
increases the cytokine and endocrine responses to LPS in humans (52). It should be noted
that the induction of hypoglycemia does not always result in insulin resistance. For example,
injection of adiponectin, a hormone produced by adipocytes, lowers circulating glucose by
enhancing insulin sensitivity (53,54). Along these arguments, we did not measure the
activity of AMPK or any of its down stream targets. The reduction of glucose production
through AMPK is mediated by an increase in insulin sensitivity (36,55-57).It is unlikely that
LPS invokes AMPK to trigger hypoglycemia because LPS invokes insulin resistance.
LPS mediates its effects by similar pathways in mice and humans. For example, TLR4
mutations lower LPS responsiveness in both (14,58). The suppression of the TLR4, MyD88,
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NFκB pathway in humans offers a therapeutic strategy for the management of circulating
glucose levels and insulin resistance. This is consistent with the elevation of TLR4 activity
in obese type 2 diabetics and the anti-diabetic effects of aspirin and salicylate through
inhibition of IKKβ (6,59,60).
The lipid moiety of LPS, called as Lipid A, induces hypoglycemia similar to LPS (61). In
the present study, Lipid A inhibited glucose production in hepatocytes and hepatoma cells
(data not shown). These observations suggest that derivatives of Lipid A that block TLR4
can have therapeutic potential.
In summary, the present study shows that insulin resistance is a secondary effect of LPS-
induced hypoglycemia through the TLR4, MyD88, NFκB pathway.
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Figure 1. LPS-induced hypoglycemia depends on TLR4 and MyD88, but not on LPS induction of
TNFα
(A) TLR4+/+ and TLR4−/− mice were injected with increasing doses of LPS, and plasma
glucose was measured after 4 hours. (B) MyD88+/+ and MyD88−/− mice were injected with
LPS (0.5 mg/kg), and plasma glucose was measured at 1, 2, 3 and 4 hours after injection.
(C) TNFα+/+ and TNFα−/− mice were injected with LPS (0.5 mg/kg). Plasma glucose (left)
and TNFα (right) were measured 8 hours after LPS injection. Results represent the mean ±
SEM from n=5 mice per group. * Indicates significant differences between LPS and control
groups (p<0.05).
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Figure 2. LPS inhibits the production and utilization of glucose
(A) Wild-type mice were injected with LPS (0.5 mg/kg) or saline. Glucose was measured
before injection and at 4, 6, 8, 12, 16 and 24 hours after injection. (B) Eight hours after LPS
or saline injection, mice received trace amounts of 3H-glucose by intravenous injection. The
disappearance of 3H-glucose was used to determine the rate of glucose utilization. The rate
of glucose utilization also represents. (C) The trace amounts of 3H-glucose, the stress of
injection and blood sampling did not affect circulating levels of glucose. (D) The
disappearance of radioactivity in plasma. (E) HPLC analysis of plasma collected 3 (black), 9
(blue), 15 (green) and 21 (red) minutes after glucose injection in 1 mouse. (F) Rat
hepatocytes were incubated in medium with or without LPS (2.5 μg/ml), and glucose
production was measured. Results represent the mean ± SEM from n=5 mice per group or
n=3 tissue culture replicates. * Indicates significant differences between LPS and control
groups (p<0.05).
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Figure 3. LPS inhibition of glucose production depends on NFκB
(A) EMSAs of liver nuclear extracts from mice LPS (0.5 mg/kg) and saline injected mice.
(B) Rat hepatoma cells were transduced by retroviral vector encoding either green florescent
protein (GFP) or IκB–Super Repressor (IκB-SR), a degradation resistant IκB mutant that
blocks NFκB activation. DNA integration and mRNA expression of IκB-SR were confirmed
by PCR. (C) Rat hepatoma cells expressing GFP or GFP/IκB–SR were incubated in medium
with or without LPS (2.5 μg/ml). Glucose secretion from hepatoma cells into glucose-free
medium was measured over a period of 8 hours. Results represent the mean ± SEM from
n=3 tissue culture replicates. * Indicates significant differences between LPS and control
groups (p<0.05).
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Figure 4. LPS and inhibit glucose production by different pathways
(A) Rat hepatoma cells were exposed to insulin (100 nM), the PI3K inhibitor LY294002 (33
μM) and/or LPS (2.5 ug/ml). Results represent the mean ± SEM from n=3 tissue culture
replicates. * Indicates significant differences between LPS and non-LPS treatment groups
(p<0.05). (B) TLR4+/+ and TLR4−/− mice were injected with insulin (0.75 U/kg). Glucose
was measured at 15, 30, 45, 60, 90 and 120 minutes after injection. Results represent the
mean ± SEM from n = 5 mice per group. Significant differences between TLR4+/+ and
TLR4−/− mice were not detected at any time point.
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Figure 5. Glucose intolerance and hyperinsulinemia after recovery from LPS-induced
hypoglycemia are linked to TLR4
(A) TLR4+/+ and TLR4−/− mice were injected with glucose (2.5 mg/g) 48 hours after LPS or
saline injection. Plasma glucose was measured at 15, 30 60, 90 and 120 minutes after
glucose injection. (B) TLR4+/+ and TLR4−/− mice were injected with glucose (0.5, 1, 2 or 4
mg/g) 48 hours after LPS or saline injection. Plasma insulin was measured 15 minutes after
insulin injection. Results represent the mean ± SEM from n=5 mice per group. * Indicates
significant differences between mice primed by LPS and saline (p<0.05).
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